Paloma Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Paloma Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-70,040	Closed	-$4.8M	–	1767
2024 Q2	$4.8M	Buy	+70,040	New	+$4.86M	0.14%	134

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Paloma Partners's ITCI Position: Q3 2024 in Review

Paloma Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 70,040 shares — an estimated $4.8M sold.

Paloma Partners first reported a position in ITCI in Q2 2024 and held it in 1 quarter. The position peaked at $4.8M in Q2 2024. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Paloma Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 70,040 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $4.8M.
Paloma Partners first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 1 quarter.
Paloma Partners's Intra-Cellular Therapies Inc. position peaked at $4.8M in Q2 2024.
354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.